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Abstract: Breast cancer is a heterogeneous disease, encompassing a large number of entities 
showing different morphological features and having clinical behaviors. It has became apparent 
that this diversity may be justified by distinct patterns of genetic, epigenetic, and transcriptomic 
aberrations. The identification of gene-expression microarray-based characteristics has led to 
the identification of at least five breast cancer subgroups: luminal A, luminal B, normal breast-
like, human epidermal growth factor receptor 2, and basal-like. Triple-negative breast cancer 
is a complex disease diagnosed by immunohistochemistry, and it is characterized by malignant 
cells not expressing estrogen receptors or progesterone receptors at all, and human epidermal 
growth factor receptor 2. Along with this knowledge, recent data show that triple-negative breast 
cancer has specific molecular features that could be possible targets for new biological targeted 
drugs. The aim of this article is to explore the use of new drugs in this particular setting, which 
is still associated with poor prognosis and high risk of distant recurrence and death.
Keywords: basal-like breast cancer, estrogen–progesterone receptors, gene-expression microar-
ray, human epidermal growth factor receptor 2, chemotherapy, target therapy
Introduction
In 2014, about 235,030 new cases of breast cancer (BC) are expected in the USA, with 
40,430 cancer-related deaths.1 In 2009, approximately 170,000 BC cases were of the 
triple-negative (TN) phenotype,2 accounting for 10%–20% of invasive BC.1–3
Triple-negative breast cancer (TNBC) is defined by its lack of estrogen-receptor 
(ER) and progesterone-receptor (PR) expression, along with the absence of human 
epidermal growth factor receptor 2 (HER2) overexpression or gene amplification.3 
Nowadays, TNBC is one of the most attractive areas of research in oncology. Reasons 
for this scientific interest are the lack of a recognized target for molecular-oriented 
therapy, which makes TNBC a new orphan disease. Furthermore, TNBC is a biologi-
cally aggressive neoplasia with a strong association with distant recurrence, visceral 
metastases, and death when compared with other BC types.4 Recurrence often occurs 
within 3 years of diagnosis, while 5-year mortality rates appear to be increased after 
initial diagnosis.4 Moreover, metastatic setting implies a much shorter median time 
from relapse to death.5 Particularly, the median survival of advanced TNBC is at best 
12 months, much less than the median duration of survival observed in other advanced 
BC subtypes.5
Considering the gene-expression analysis, it appears very clear that TNBC is a 
heterogeneous BC form, which shows only partial overlapping features with so-called 
basal-like (BL) breast cancer (BLBC).6–8 In fact, not all TN tumors are identified as 
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BL by gene expression, and not all BL tumors are TN; the 
discordance rate between the two definitions is 20%–30%.9 
More recently, subtyping of three large clinical trials (GEI-
CAM/9906, MA.12, and MA.5) using the PAM50 quantita-
tive real-time reverse transcription-polymerase chain reaction 
(qRT-PCR)-based assay revealed that approximately 30% of 
tumors identified as TN by central pathology review do not 
fall into the BL subtype category.10 Therefore, significant 
biological heterogeneity exists within the group of patients 
diagnosed with TN disease, with the BL subtype being 
undoubtedly the most frequently observed (about 75%).11
Very recently, Lehmann et al12 analyzed gene-expression 
profiles from 21 BC datasets and confirmed the concept that 
a significant heterogeneity within TNBC and BC tumors 
occurs. According to this analysis, there are six different 
TNBC subtypes: two BL (BL1 and BL2), an immunomodula-
tory, a mesenchymal (M), a mesenchymal stem-like, and a 
luminal androgen receptor.12
In this regard, investigators identified BC cell lines repre-
sentative of each of these molecular subtypes with different 
sensitivities to various targeted therapies currently under 
clinical investigation, providing an attractive platform for 
future drug development in TNBC.13
These fascinating results constitute the basis for future 
approaches in TNBC, using both cytotoxic drugs not clas-
sically used in BC (platinum salts) or alternative schedules 
(dose dense), and new drugs (poly-ADP-ribose-plymerase-1, 
agents targeting the epidermal growth factor receptor 
(EGFR), multi-tyrosine-kinase inhibitors, or antiangiogenic 
agents).
The aim of this paper is, therefore, to discuss targeted 
agents with a possible activity against TNBC.
Perspectives in treatment of TNBC: 
targeting the molecular feature
Hormonal therapy
Recent guidelines dictate that a hormonal receptorial 
 threshold ,1% should be used;14 about this, the St Gallen 
expert group recommends adjuvant endocrine therapy for 
any detectable hormone receptor.15
Recent findings show that other isoforms of ERs could 
be present that are not detected by the current techniques; 
in this way BCs expressing some form of ERs are labeled 
 “hormone-receptor negative” BCs.
Three forms of ERs, ERα, ERβ, and G-protein-coupled 
receptors (GPCRs), are currently known; they are co-
expressed in a large fraction of normal and BC tissues. 
Particularly the first two, the classical steroid receptors, are 
localized not only in the plasma membrane,16 but also in the 
cytosol and/or nucleus; traditionally, they exert their effects 
at the genomic level. In recent years, however, a large number 
of reports has described membrane-associated ERs, such 
as GPCRs.17,18 Recent studies showed that rapid effects are 
mediated by these novel transmembrane Estrogen receptors, 
also known as G- protein coupled receptor 30 (GPR 30).19–21 
Anyhow, ERs play important roles in the initiation and pro-
gression of estrogen-related BC.22
ERα in several studies seems to be responsible for gov-
erning estrogen-dependent growth, response to endocrine 
therapy,23 and prognosis in ERα-positive BC; ERβ seems to 
be an antagonist against ERα effects.24–28 According to some 
data, it seems that ERβ functions are different when it is co-
expressed with ERα than when it is expressed alone.29,30 In 
the same way, GPR30 plays a role in the regulation of cellular 
growth, proliferation, and apoptosis.31 Moreover, effects medi-
ated by GPR30 are maintained when classic ERs are absent 
or blocked. In addition, GPR30 is involved in drug resistance, 
implying that GPR30 may be an important therapeutic target 
for estrogen-related tumors.  Blocking both GPR30 and classic 
ERs may be a better strategy for the treatment of estrogen-
related tumors. However, despite the indications that GPR30 
may represent a novel  estrogen-binding receptor, a description 
of its ligand-binding properties appears to be lacking in the 
scientific literature.32 Interestingly, ER antagonists/selec-
tive estrogen-receptor modulators, such as tamoxifen and 
ICI182,780, have also been shown to bind GPR30, which is 
consistent with previous functional studies showing that these 
same compounds are agonists for GPR30.32,33 Moreover, with 
the recent report of a highly selective, nonsteroidal GPR30 
agonist, future studies of GPR30 function should be greatly 
facilitated by this novel reagent.34 However, some breast 
cells express only ERα, whereas other breast cells express 
only ERβ. There are also breast cells that express neither 
ERα nor ERβ.35
Anyhow, the ER status in BC patients has been tradition-
ally defined by the presence or absence of ERα; in fact, the 
ER-negative status of TNBC patients is regularly negative for 
ERα but not necessarily negative for ERβ;36 indeed, several 
studies have reported expression of ERβ in a substantial frac-
tion of ERα-negative and TNBC patients. Gruvberger-Saal 
et al examined ERα and ERβ expression in patients treated 
with Tamoxifen (TAM) for 2 years, observing that ERβ 
was significantly associated with increased distant disease-
free survival (DFS); furthermore, ERβ was an independent 
marker within the ERα-negative tumors.37 Importantly, ERβ1 
positivity was significantly associated with better survival 
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in patients with ERα-/PR-negative or triple negative (TN)-
tumors. On this basis, ERβ1 and ERβ variants may play some 
roles in estrogen signaling and the pathogenesis of TNBC; 
however, this hypothesis was not confirmed by clinical and 
histopathological parameters.38
Furthermore, approximately 75% of all BCs are ERα 
positive, which is a good predictor of treatment response.39–41 
The ER-α gene is composed of six functional domains 
encoded by eight exons that commonly produce a 66.2 kDa 
protein (ER-α66).42 Furthermore, ER-α66 is the isoform 
detected in clinical practice. There are at least two different 
isoforms of ER-α66 described in human BC:43 ER-α46 and 
ER-α36.44,45 The importance of these isoforms lies in the 
possibility that some TNBCs are expressing some truncated 
ERa receptors that could be a target for anti-estrogen therapy. 
Particularly, ER-α36 is a new isoform of ERs without the 
transcriptional activation domains of the classical ER-α66.46 
ER-α36 has been shown to transduce the membrane-initiated 
steroid signaling cascade, and acts as a dominant-negative 
effector of estrogen-dependent and -independent transactiva-
tion, mediated by ER-α66.47,48 ER-α66 expression can also 
be detected in the cytoplasm of BC cells after long-term 
treatment with tamoxifen, coinciding with resistance to 
the drug.48
Moreover, Shi et al indicated the importance of ER-α36 
in the development of endocrine resistance in a subgroup 
of invasive BC that exhibits co-expression of ER-α66 and 
ER-α36. The functional importance of ER-α36 is related to 
its non-genomic ER activities; according to this hypothesis, 
activation of the mitogen-activated protein kinase/ extracellular 
signal-regulated kinase (MAPK/ERK) signaling pathway 
plays a major role. The MAPK/ERK signaling pathway is acti-
vated in response to both estrogens and antiestrogens, which 
might be of particular importance for ER-α66-negative BC, 
since this subgroup might still respond to antiestrogen-based 
therapy.45 Previous  experiments demonstrated that antiestro-
gens induce a stronger and more prolonged activation of the 
MAPK/ERK signaling pathway than the estrogens.45
The androgen cluster is a particular kind of BC showing 
the androgen receptor (AR) in a very similar way to ER + 
PgR + BC.49 Until 1970, androgen therapy was one of the 
strategies used to manage BC. Moreover, the presence of 
the AR has been well known for a long time; even while 
the clinical use of this knowledge has been abandoned, 
experimental studies have continued, showing that the AR 
is the most commonly expressed nuclear hormone recep-
tor in BC.50–52 Recent studies suggest that 10%–35% of all 
TNBC presents an AR-positive gene-expression profile; 
moreover, these TNBCs are frequently apocrine BC51, 
even if some other experiences show no significantly 
different histopathological features between AR-positive 
and  AR-negative BC.53
Anyhow, AR-targeting has been introduced recently as a 
novel therapeutic option in TNBC,54 and a Phase II trial of 
nonsteroidal antiandrogen treatment is ongoing in women 
with advanced AR-positive, ER-negative, PR-negative BC. 
The preliminary results of this trial suggest attractive  benefit.55 
On this basis, other trials are investigating the use of androgen 
inhibition in TNBC.
Poly (adenosine diphosphate-ribose) 
polymerase inhibitors
Genomic integrity and cell survival are critically related 
to coordinated pathways of DNA repair.56 Poly  (adenosine 
diphosphate-ribose) polymerase (PARP) enzymes – 
 particularly the most abundant isoform, PARP1 – play a key 
role in these pathways by mediating the repair of single-strand 
DNA breaks via base-excision repair.57  Consequently, loss 
of PARP activity results in the accumulation of single-strand 
breaks, which are normally repaired by double-strand homolo-
gous recombination pathways that include the important 
tumor-suppressor proteins BRCA1 and BRCA2.58 It is well 
known that germ-line BRCA1 and BRCA2 mutations are 
associated with a high risk of oncogenesis for breast and ovar-
ian cancers.59 TNBC shares clinical and pathological features 
with hereditary BRCA1-related BC; in sporadic TNBC, dys-
regulation of BRCA1 has been frequently observed together 
with other defects in homologous recombination pathways.60,61 
A preclinical study showed that TNBC cells are more sensitive 
to PARP1 inhibitors when compared with non-TNBC cells, 
and that PARP inhibition acts synergically in association 
with gemcitabine and cisplatin in TN cells but not in lumi-
nal cancers.62 All this evidence provides a strong rationale 
for developing a new therapeutic approach to TNBC based 
on targeting the DNA-repair defects via PARP inhibition. 
Several PARP inhibitors, such as olaparib, veliparib, iniparib, 
niraparib, and rucaparib, are currently under early develop-
ment in TNBC or BRCA-mutated BC.
Establishing which subtypes of BC are most indicated 
for PARP inhibitor treatment, and how to identify these, 
is a matter of strategic importance for further clinical 
development of this class of anticancer agents. Despite 
their extremely high therapeutic potential, more research 
on the biology of the numerous members of the PARP 
families and on their role in the molecular pathogenesis 
of BRCA1- and BRCA2-mutated is necessary before we 
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can claim to understand the utility of the PARP inhibitors 
in clinical oncology.
Olaparib
Olaparib, an oral PARP inhibitor, demonstrated its antitu-
mor activity in patients who were carriers of the BRCA1 
or BRCA2 mutation in a Phase I trial.63 Moreover, olaparib 
has been investigated as a single agent in BRCA1- and 
 BRCA2-mutated women with advanced BC in a Phase II 
trial.64 In this nonrandomized trial, patients were assigned to 
one of two sequential cohorts; in the first cohort oral olaparib 
at 400 mg twice daily was given continuously, while in the 
second one a lower dose of 100 mg twice daily was used. 
The primary endpoint was objective response rate (RR). All 
patients had received previous chemotherapy. The objective 
RR was confirmed in 11 of 26 patients in cohort 1 and six 
of 24 in cohort 2. The clinical benefit rate (CBR) was 52% 
for cohort 1 and 26% for cohort 2. Median progression-free 
survival (mPFS) was 5.7 months for cohort 1 and 3.8 months 
for cohort 2.64 Furthermore, olaparib toxicity was generally 
mild and manageable, with the most frequent adverse events 
(AEs) occurring in cohort 1 (fatigue, nausea, vomiting, 
and anemia). The results of this study provide an important 
proof-of-concept for PARP inhibition in BRCA-deficient BC; 
selecting patients with TNBC who are also BRCA deficient 
could isolate a patient population who may be more recep-
tive to treatment with PARP inhibitors. It is interesting to 
observe that there is no reported activity for olaparib against 
non-BRCA-mutant or unreported BRCA status.65
In another Phase II, multicenter, open-label, non-randomized 
study, women with advanced high-grade serous and/or undif-
ferentiated ovarian carcinoma or TNBC were enrolled and 
received olaparib 400 mg twice a day.66 Patients were stratified 
according to whether they had a BRCA1 or BRCA2 mutation 
or not. The primary endpoint was objective RR. In the TNBC 
cohort, no RECIST (Response Evaluation Criteria In Solid 
Tumors) validated responses were reported at the first stage, 
so this cohort was closed.
A Phase I study evaluated the safety, tolerability, and 
efficacy of olaparib in combination with paclitaxel in 
patients with metastatic TNBC (mTNBC).67 Patients who 
had received #1 prior cytotoxic regimens for mTNBC were 
treated continuously with olaparib plus weekly paclitaxel. 
Nineteen patients received treatment. Patients in cohort 
2 received olaparib and paclitaxel at the same doses and 
schedule as patients in cohort 1. For patients in cohort 2, 
upon first occurrence of grade $2 neutropenia, the paclitaxel 
dose was omitted or delayed; olaparib dosing was continued. 
Objective RR in cohort 1 was 3/9 patients and in cohort 2 
was 4/10 patients.
This agent is currently undergoing clinical evaluation in 
combination with paclitaxel in a Phase II single-arm trial68 
and in combination with carboplatin and/or paclitaxel in a 
Phase I study69 – both trials are in patients with mTNBC. 
Olaparib is also undergoing investigation in combination 
with cisplatin in a Phase I single-arm trial in neoadjuvant 
approach for locally advanced TNBC.70
veliparib
Veliparib is an oral PARP1 and PARP2 inhibitor. In a single-
arm Phase II trial, the activity of veliparib and temozolomide 
(TMZ) was tested in 41 metastatic BC patients (15 TNBC 
patients).71 TMZ has minimal activity in BC, which is prob-
ably due to the methylated DNA-repair adducts by the base-
excision repair pathway.71 The primary endpoint in the study 
was overall RR. Best responses for 24 patients evaluable at the 
time of abstract submission included one complete response 
(CR), two partial responses (PRs), seven stable diseases 
(SDs), and 14 progressive diseases (PDs); 17 patients were 
not yet evaluable for response. Therefore, veliparib and TMZ 
may be a promising new strategy in mTNBC.
In a subsequent expansion cohort, first-line therapy for 
metastatic BC and prior PARP inhibitor therapy were allowed, 
and eligible patients were required to have a known deleterious 
BRCA1 or BRCA2 mutation identified from prior clinical 
testing.72 All patients received veliparib and TMZ. Twenty eli-
gible patients were enrolled. Best response for the 20 patients 
evaluable at the time of abstract submission included three 
PRs, six SDs, eleven PDs, and a clinical benefit rate (CBR) 
of 45%. Combined with the initial cohort of eight known 
carriers from the original 41 patients, the total RR was 25% 
(7/28) and CBR was 50%. The RR was 40% (6/15) in patients 
without prior platinum treatment, and 9% (1/11) in patients 
with prior platinum treatment. The mPFS for the 20 BRCA 
carriers was 85 days, and among patients with prior platinum 
treatment compared with no prior platinum, the mPFS was 
70 and 179 days, respectively.
iniparib
Iniparib was initially developed as a PARP inhibitor, but recent 
data suggest that it does not show characteristics typical of 
this class and its exact mechanism of action remains to be 
elucidated.73 The cellular effects of iniparib include the induc-
tion of γ-H2AX foci (a marker of DNA damage) and cell-
cycle arrest in the G2/M phase in tumor cell lines.74 Iniparib 
also potentiates the cell-cycle effects of DNA  damaging 
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 modalities in tumor cell lines, and antiproliferative activity 
has been demonstrated in a TNBC-related cell line.75
Results of a Phase II trial (Table 1) in patients with 
mTNBC showed that adding iniparib to gemcitabine and 
carboplatin significantly improved CBR and progression-free 
survival (PFS) (P=0.01) compared with chemotherapy 
alone.76 The median overall survival (mOS) was also sig-
nificantly improved in the arm containing iniparib (P=0.01). 
There were essentially no differences in AE incidence 
between the two treatment groups, suggesting that iniparib 
was very well tolerated.
Results of a multicenter Phase III trial assessing the same 
iniparib combination in advanced TNBC failed to meet the 
primary study endpoints (Table 1).77
Ongoing clinical trials will further evaluate the benefits 
of weekly or biweekly iniparib in combination with gemcit-
abine and carboplatin in the advanced setting,78 iniparib and 
PF-01367338 in neoadjuvant and adjuvant settings, respec-
tively, as well as other promising PARP inhibitors.79,80
Anti-eGFR
Different studies have indicated that EGFR is frequently over-
expressed in TNBC and it is a negative prognostic factor,81,82 
suggesting a potential role for EGFR-targeted therapies in 
this subset of patients. There are randomized data on EGFR 
inhibitors, including the monoclonal antibody cetuximab and 
the tyrosine-kinase inhibitors (TKIs) erlotinib and lapatinib 
in the management of TNBC.
In a large randomized Phase II trial, 173 patients with 
mTNBC, who had received no more than one previous line 
of chemotherapy for metastatic disease, received cisplatin, 
with or without cetuximab (Table 1).83 The objective RR 
was 20% with cisplatin plus cetuximab and 10% with cis-
platin alone (P=0.11). Cisplatin plus cetuximab resulted in 
a longer mPFS (P=0.032) and an approximately the same 
mOS (P=0.31) compared with cisplatin alone. Although 
the RR was doubled in the combination arm, it did not meet 
the prespecified primary endpoint of the study and was 
not found to be statistically significant (Table 1). Efforts 
are underway to identify those patients with mTNBC who 
benefit from cetuximab treatment, which may be correlated 
with lower expression of the α-crystallin B chain (encoded 
by the CRYAB gene), higher expression of phosphatase and 
tensin homologue (PTEN) and lack of KRAS expression in 
patients with BLBC.
In another randomized Phase II trial, 102 patients with 
mTNBC received cetuximab alone (arm 1) or cetuximab asso-
ciated with carboplatin (arm 2).84 Two of 31 patients in arm 1 
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experienced PR and one had durable SD (CBR =10%). Of 
71 patients treated in arm 2, one experienced CR and eleven 
experienced PR, for an overall RR of 17%. Ten had prolonged 
SD (CBR =31%). Patients treated with the combination, 
after progression while receiving single-agent cetuximab, 
had similar results (RR =16%; CBR =28%). Response was 
unrelated to previous lines of therapy. The mOS was 7.5 
months for arm 1 and 10.4 months for arm 2.
The addition of cetuximab to irinotecan and carboplatin 
in first- and second-line metastatic BC patients in a Phase II 
trial resulted in improved RR among a subset of TNBC 
patients (objective RR 30% without cetuximab versus 49% 
with cetuximab).85 However, no improvements in either PFS 
or overall survival (OS) were apparent in the TNBC subgroup, 
and cetuximab combination resulted in a substantial increase 
in diarrhea compared with chemotherapy alone.
A randomized Phase II trial assessed the combination of 
erlotinib with carboplatin and docetaxel in the neoadjuvant 
treatment of TNBC patients and demonstrated promising 
activity with a pathological complete response (pCR) of 
40%.86 In addition, patients were equally randomized between 
two erlotinib arms. Patients in arm 1 received erlotinib during 
all six cycles of chemotherapy and patients in arm 2 received 
erlotinib only during the last four cycles of chemotherapy, 
with only minimally increased toxicity. Five of 28 patients 
carried a BRCA mutation (two BRCA1 deleterious, two 
BRCA2 deleterious, one BRCA1 uncertain). The overall pCR 
rate was 39%. BRCA mutation status strongly correlated with 
pCR, with a rate of 100% in BRCA mutated patients, com-
pared with 27% in those without BRCA mutation (P=0.006). 
Baseline EGFR and/or p53 expression of 10% was associated 
with a lower pCR rate in BRCA noncarriers (pCR: 12% vs 
66%, P=0.025).
Retrospective data from two randomized Phase II trials 
demonstrated modest activity for gefitinib in combination 
with standard neoadjuvant chemotherapy, and a lack of activ-
ity for lapatinib in combination with paclitaxel in advanced 
TNBC patients.3,87
Ongoing prospective, randomized EGFR clinical trials, 
such as those investigating combinations of cetuximab with 
ixabepilone in both the early88 and advanced89 settings, will 
better define the role of these agents in TNBC.
Mammalian target of rapamycin inhibitors
Everolimus (RAD001) is an oral inhibitor of serine-threonine 
kinase mammalian target of rapamycin (mTOR), show-
ing broad antitumor activities in preclinical models.90,91 
An interesting study investigated the antitumor activity of 
everolimus in nine different TNBC cell lines.92 The study 
suggested that everolimus is a promising agent for the treat-
ment of TNBCs, especially BLBC. Basal markers (EGFR 
and CK5/6) or cancer stem-cell markers (E-cadherin, snail, 
or twist) may be predictive markers of the response to 
everolimus in TNBCs.
Rapamycin potentiates the cytotoxicity of paclitaxel in 
cell lines with phosphoinositide 3-kinase (PI3K)/PTEN/
Akt aberrations, suggesting that combination therapy 
may be effective in these tumors.93 In this light, a Phase II 
study investigated the role of everolimus added to standard 
neoadjuvant chemotherapy in patients with TNBC.94 Fifty 
patients were randomly assigned to 5-FU, epirubicin, and 
cyclophosphamide with docetaxel (FEC-T), or to FEC-T 
with everolimus 30 mg weekly. Twelve-week RR evaluated 
by ultrasounds were 29.6% vs 47.8%, respectively (P=0.075). 
There were no differences in RR at 24 weeks (P=0.27). The 
pCR rates after chemotherapy completion were 25.9% for 
FEC-T and 30.4% for FEC-T plus everolimus (P=0.76). In 
conclusion, adding everolimus to neoadjuvant paclitaxel 
showed a trend toward an improvement in the 12-week RR, 
but it did not improve the pCR rate in TNBC.
Another study evaluated the effects of co-inhibition of 
mTOR (using rapamycin) and EGFR (using lapatinib) in 
TNBC cell lines and nude mice models,95 showing that the 
combination therapy results in synergistic effects in TNBC 
models in vitro and suppresses TN tumor growth in vivo.
Anti-vascular endothelial growth factor/
vascular endothelial growth factor-
receptor monoclonal antibodies
TNBC is a highly proliferative neoplasm that needs constant 
angiogenesis throughout all the phases of its development, inva-
sion, and metastasis.96 Intra-tumoral expression of the vascular 
endothelial growth factor (VEGF) is significantly higher in 
TNBC than in non-TNBC, providing a biological rationale for 
targeting this pathway in the treatment of TNBC patients.97
The anti-VEGF monoclonal antibody bevacizumab (BV) 
has been shown to increase the RR and PFS of patients with 
metastatic BC when added to first-line chemotherapy in three 
randomized Phase III trials.99–101 A meta-analysis of TNBC 
subgroup data from these first-line Phase III trials revealed 
a 35% reduction in the risk of progression (hazard ratio 
[HR] =0.65) and a benefit in mPFS of 2.7 months (P,0.0001) 
when BV was added to chemotherapy regimens, compared 
with chemotherapy alone.98
An open-label, randomized, Phase III trial compared the 
efficacy and safety of paclitaxel with or without BV, as initial 
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treatment for metastatic BC.99 Particularly, a retrospective 
subgroup analysis of the E2100 trial suggested that the addi-
tion of BV to paclitaxel reduced the risk of progression in 
first-line TNBC patients by 51% and doubled the mPFS.
The efficacy and safety of combining BV with docetaxel 
as first-line therapy for HER2-negative, locally recurrent, 
or metastatic BC was investigated in a three-arm, placebo-
controlled, Phase III trial.100 In this study, patients were ran-
domly assigned to docetaxel plus either placebo or BV 7.5 
or 15 mg/kg every 3 weeks. In the TNBC subgroup, mPFS 
was 8.2 months in the docetaxel in combination with BV 15 
mg/kg arm, and it was 6.2 and 5.4 months in the BV 7.5 mg/
kg and placebo arms, respectively. The combination of BV 
with docetaxel had no major impact on the toxicity profile 
of docetaxel. Grade 3 to 4 AEs of special interest were more 
common in the BV arms than the placebo group, and most of 
the differences were attributable to hypertension, neutropenia, 
and febrile neutropenia. This randomized, double-blind study 
confirmed the clinical benefit of combining BV with a taxane, 
as previously reported in trial E2100. Taken together, these 
studies suggest that the combination of BV with taxane-based 
chemotherapy should be considered as an option for the first-
line treatment of HER2-negative metastatic BC.
Moreover, Regimens in Bevacizumab for Breast 
Oncology (RIBBON)-1, a Phase III, randomized, and 
placebo-controlled trial, was designed to evaluate the effi-
cacy and safety of BV in combination with chemotherapy 
regimens, including non-taxane, such as capecitabine, used 
as initial chemotherapy-based treatment of metastatic BC.101 
In the capecitabine cohort, mPFS increased from 4.2 months 
in the placebo arm to 6.1 months in the BV arm. In the 
taxane/anthracyclines cohort, mPFS was 6.2 months in the 
placebo arm and 6.5 months in the BV arm. The results of 
the RIBBON-1 trial indicated no clear benefit for TNBC 
patients who added BV to chemotherapy.
Regarding the second line of treatment, the RIBBON-2 
trial (Table 1) was designed to evaluate the efficacy and 
safety of combining BV with chemotherapeutic schedules 
commonly used for patients affected by metastatic BC 
who had received one previous cytotoxic regimen in the 
metastatic setting.102 In patients with TNBC, BV combined 
with chemotherapy resulted in a 3.3-month improvement 
in mPFS (P=0.0006), with a trend toward improved OS 
(P=0.0534).
BV has also been investigated in the neoadjuvant setting, 
and data from two large randomized clinical trials in patients 
with HER2-negative operable BC have been presented. The 
first, the GeparQuinto trial, evaluated the rate of pCR after 
neoadjuvant epirubicin, cyclophosphamide, and docetaxel 
chemotherapy with and without the addition of BV in patients 
with TNBC.103,104 The pCR rates were 27.9% without and 
39.3% with BV (P=0.003).
In the second trial, the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-40 study, patients were ran-
domly assigned to receive neoadjuvant therapy consisting of 
docetaxel, docetaxel plus capecitabine, or docetaxel plus gem-
citabine for four cycles, with all regimens followed by treatment 
with doxorubicin-cyclophosphamide for four cycles.104 Patients 
were also randomly assigned to receive or not to receive BV 
for the first six cycles of chemotherapy. The addition of BV 
significantly increased the rate of pCR; when this rate was 
examined according to hormone-receptor status, the effect of 
BV was more pronounced in the hormone-receptor-positive 
subset (15.1% without BV vs 23.2% with BV [P=0.007]), 
with a weaker effect in the hormone-receptor-negative subset 
(47.1% without BV vs 51.5% with BV [P=0.34]).
The differences in the results from the two trials could 
be attributed to the differences in the definition of HER2 
negativity in the patients and to the different regimens that 
they received. Moreover, in the Phase 2 Cancer and Leu-
kemia Group B (CALGB)/Alliance 40603 trial, a total of 
454 women with operable stage II or III TNBC were ran-
domly assigned to receive different schedules of treatment: 
standard neoadjuvant paclitaxel chemotherapy, including 
doxorubicin and cyclophosphamide, standard neoadjuvant 
therapy plus carboplatin, standard neoadjuvant therapy plus 
BV, or standard neoadjuvant therapy plus both carboplatin 
and BV.105 The pCR rate in breast tissue with or without neo-
adjuvant carboplatin was 60% versus 46% (odds ratio [OR] 
=1.76; P=0.0018); in the BV arm, pCR was 59% compared 
with 48% in the non-BV arm (OR =1.58; P=0.0089). When 
carboplatin and BV were used in combination against the 
chemotherapy backbone, the highest pCR rate was achieved, 
67%, but the P-value for the carboplatin/BV interaction was 
0.52, indicating the lack of a synergistic effect.
In an adjuvant setting, the BEATRICE study, a randomized 
Phase III trial, assessed the addition of BV to chemotherapy 
for women with TNBC.106 Almost two-thirds of patients in both 
groups had node-negative disease. There was no difference 
between the chemotherapy-alone group and BV group in DFS 
(HR =0.87; 3-year invasive DFS =82.7% in the chemotherapy 
group versus 83.7% in the BV group; P=0.18). All secondary 
efficacy endpoints seemed to favor BV, but none was statisti-
cally significant.
While BV binds specifically to the ligand, vascular endothe-
lial growth factor-A (VEGF-A), and all its isoforms, it has 
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limited binding affinity for other vascular endothelial growth 
factor-receptor (VEGFR) ligands, VEGF-B, and VEGF-C. 
Newer antiangiogenic agents bind to VEGFR-2 and thus 
prevent all ligand binding to this target.  Therefore, targeting 
VEGFR in this way could potentially lead to a more complete 
target inhibition and a more effective angiogenesis block. In 
this regard, the monoclonal antibody ramucirumab (IMC-
1121B, ImClone) targeting VEGFR-2 is currently under inves-
tigation in combination with docetaxel in a Phase III clinical 
trial in patients with HER2-negative metastatic BC.107
Anti-veGFR TKis
Cell surface-receptor tyrosine kinases, including VEGFRs, 
are critical to angiogenesis, and the effects of two TKIs 
on endothelial cell proliferation have been evaluated in 
TNBC.
The anti-VEGFR TKIs sunitinib and sorafenib have 
shown some interesting degrees of activity in BC in clinical 
studies with substantial TNBC populations.
Sunitinib
Sunitinib was investigated in a preliminary Phase II trial 
as a single agent in patients with metastatic BC who had 
received prior anthracycline and taxane therapy. Neither 
steroid receptor nor HER2 status appeared to correlate with 
clinical response. Among the patients with TNBC, the RR 
was 15%, and 11% in the total population.108
Another randomized (Table 1), open-label Phase II 
trial was designed to test the hypothesis that the PFS of 
patients receiving sunitinib monotherapy (37.5 mg/day) on a 
 continuous-daily-dosing schedule would be superior to that 
obtained with single-agent standard-of-care (SOC) chemo-
therapy in patients with previously treated TNBC. Almost all 
patients had received prior treatment containing an anthracy-
cline and a taxane; approximately three-quarters of patients had 
received prior chemotherapy for advanced disease. Thirteen 
percent of patients received prior BV therapy in both arms. The 
mPFS was 2.0 months with sunitinib versus 2.7 months with 
SOC (P=0.888). Moreover, the mOS was not prolonged with 
sunitinib treatment compared with SOC (P=0.839).109
In a prospective and randomized Phase III study, 
patients with advanced BC were randomly assigned to 
open-label combination therapy (sunitinib and docetaxel) or 
 monotherapy (docetaxel). There was no difference in mPFS 
(P=0.265) and mOS (P=0.904) between the two arms. The 
overall response rate (ORR) was significantly higher with the 
combination than with monotherapy (P=0.001). Duration of 
response was similar in both arms.110
Sorafenib
Sorafenib is a multi-kinase inhibitor with antiangiogenic/
antiproliferative activity. Bianchi et al described the results 
of single-agent sorafenib in metastatic BC.111 Their study 
evaluated 52 patients demonstrating a 2% RR and a 13% SD 
at 6 months. The authors concluded that further investiga-
tion of single-agent sorafenib in this patient population is 
not recommended.
A randomized, double-blind, placebo-controlled Phase II 
trial assessed sorafenib with capecitabine for locally advanced 
or metastatic HER2-negative BC. Patients were randomly 
assigned to first- or second-line capecitabine with sorafenib 
or placebo.112 The results suggest a role for the combina-
tion of sorafenib and capecitabine in BC and supported a 
multinational, double-blind, randomized, placebo-controlled 
Phase III trial assessing the addition of sorafenib to first- or 
second-line capecitabine in advanced HER2-negative BC.113 
In the NU07B1 trial, a multinational, double-blind, placebo-
controlled Phase II screening trial, patients were randomized 
to paclitaxel in combination with placebo or sorafenib. There 
was no significant difference in OS between treatment arms 
(P=0.904), but the addition of sorafenib versus placebo to 
paclitaxel significantly increased median time to progres-
sion (8.1 vs 5.6 months, respectively; P=0.0343) and ORR 
(67% vs 54%, respectively; P=0.0468).114
Another double-blind, placebo-controlled Phase II 
study enrolled patients with locally advanced or meta-
static HER2-negative BC and prior BV treatment. Patients 
were randomized to chemotherapy with sorafenib or 
placebo. The combination of sorafenib plus gemcitabine/
capecitabine provided a clinically small but statistically 
significant improvement in PFS compared with placebo 
plus gemcitabine/capecitabine (HR =0.65; P=0.02). The 
mOS was 13.4 versus 11.4 months, respectively (HR =1.01; 
P=0.95).115
New small-molecule receptor TKIs such as apatinib116 
and cediranib (in combination with olaparib)117 have reached 
Phase II clinical development in patients with TNBC.
Other target agents
7-hydroxystaurosporine
The majority of TNBCs carry mutations in TP53, a gene that 
encodes the tumor-suppressor protein p53 which is required 
for G1 checkpoint regulation in the presence of genotoxic 
stress.118,119
7-hydroxystaurosporine (UCN-01) was the first check-
point kinase 1 inhibitor introduced in clinic, although it also 
inhibits several other serine-threonine protein kinases.120,121
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In a Phase I study of UCN-01 and irinotecan in patients 
with refractory advanced solid tumor malignancies, two 
PR were observed in women with TNBC.122 Both tumors 
were deficient for p53. Therefore, it was hypothesized that 
UCN-01 and irinotecan would be an effective regimen 
in mTNBC. The goal of the Phase II trial was to further 
evaluate the association between irinotecan and UCN-1 in 
patients with mTNBC previously treated with anthracyclines 
and taxanes.123 A total of 25 patients were enrolled, and 22 
were evaluated for response. No CRs were observed. One 
PR, lasting 24 weeks, occurred in a patient with liver and 
lung metastases. Tumor from this patient was found to be 
BL carrying a TP53 mutation. Two patients had prolonged 
SD that lasted for 37 and 28 weeks, respectively. The CBR 
and the OS were 12% and 11.3 months, respectively. Unfor-
tunately, the study did not meet the predefined efficacy 
criteria for further evaluation. Among the 15 patients with 
sufficient tumor samples for TP53 mutation analysis, eight 
carried mutations in TP53. In this limited dataset, a signifi-
cantly worse OS was observed in patients with mutations 
in TP53. In particular, the median OS was 5.5 months and 
20.3 months in patients with and without TP53 mutation, 
respectively (P=0.004).
Bortezomib
Bortezomib is the first proteasome inhibitor to be approved 
for treatment for multiple myeloma and mantle-cell lym-
phoma.124,125 Particularly, bortezomib has been shown to 
block proteasome degradation of IκB, an inhibitor of nuclear 
factor-kappa B, and demonstrated remarkable antitumor 
activity against these hematological malignancies.126
Furthermore, preclinical studies have demonstrated an 
in vitro antitumor effect of bortezomib in BC models.127,128
Moreover, Tseng et al demonstrated that bortezomib 
induced significant apoptosis in TNBC cell lines but not in 
hormone-receptor-positive or HER2-overexpressing cells.129 
This study reveals a novel mechanism by which bortezomib 
induces apoptosis in TNBC cells, that is CIP2A-dependent 
p-Akt downregulation. The data showed that 50/57 (87.7%) 
of tumor samples from TNBC patients presented variable 
CIP2A expression, and, as previously demonstrated, CIP2A 
expression has been shown to correlate with disease aggres-
siveness in BC.130
Dinaciclib
Dinaciclib (MK-7965, formerly SCH727965) is a novel, 
potent, small-molecule inhibitor of cyclin-dependent kinase 
(CDK) 1, CDK2, CDK5, and CDK9.
Previously, two Phase I dose-escalation trials of dinaciclib 
administered intravenously, weekly or every 3 weeks, were 
conducted in patients with advanced malignancies and 
showed some early evidence of clinical activity131,132
A Phase II trial was designed to assess the efficacy and 
safety of dinaciclib133 compared with standard doses of 
capecitabine in women with advanced BC. The median time to 
progression was 2.73 months with dinaciclib, compared with 
4.17 months with capecitabine. The HR (dinaciclib/capecit-
abine) was 1.6. The estimated ORR following initial treatment 
with dinaciclib was 8% based on one confirmed PR among 
the 12 evaluable patients. Among the patients randomized to 
capecitabine, one patient achieved a PR for an estimated ORR 
of 7% among 14 evaluable patients. Although this trial did 
not select subpopulations of patients with BC on the basis of 
either histological or molecular markers, the confirmed and 
unconfirmed PRs achieved with dinaciclib occurred both in 
patients with ER-positive/ HER2-negative disease.
Panobinostat
Histone deacetylase inhibitors (HDACis) have emerged 
as a promising new class of multifunctional anticancer 
agents.134,135 HDACis have been linked to several downstream 
effects in tumor cell lines, such as cell-cycle arrest, induc-
tion of apoptosis, inhibition of angiogenesis, activation or 
inactivation of tumor-suppressor genes or oncogenes, and 
decreased invasion and metastases.134–136
Panobinostat (LBH589) is a potent pan-deacetylase inhibi-
tor that can block multiple cancer-related pathways.137 HDACs 
can be subdivided into two groups: zinc-dependent (Class I, 
II, and IV) and zinc-independent (Class III).138 Panobinostat 
is a potent inhibitor with activity against Class I, II, and IV 
HDACi enzymes, suggesting true pan-HDAC activity.137
To date, panobinostat has demonstrated favorable clinical 
responses, with limited toxicity.139–141
In their study, Tate et al utilized four TNBC cell lines 
as models of TNBC growth and progression.142 In confir-
mation of other preclinical research,143–145 they found that 
panobinostat induced hyper-acetylation of histones H3 
and H4, decreased proliferation and survival, and induced 
apoptosis and G2/M cell-cycle arrest.142 The panobinostat-
induced effects on cell proliferation and survival appear to 
be TNBC cell specific as the ER-positive cell lines tested 
were unaffected at all doses tested; this result was contrary to 
previously published work, which reported that panobinostat 
significantly inhibited cell survival and induced cell death 
in ER-positive and ER-negative BC cell lines, though at a 
different time point.144,146
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Dasatinib
Dasatinib, a potent oral inhibitor of the Src family of 
kinases, is approved for treating patients with Philadelphia 
 chromosome-positive leukemias.147 Preclinical studies 
showed growth inhibition of BLBC cells by single-agent 
dasatinib more frequently than other phenotypes.147–149 
Preclinical TNBC models also showed synergistic or addi-
tive dasatinib activity with chemotherapy,150 suggesting that 
dasatinib may provide clinical benefit in TNBC.
A prospective, open-label Phase II trial investigated the 
role of dasatinib in patients with locally advanced or mTNBC 
that had progressed after prior chemotherapy for advanced 
disease.151 Single-agent dasatinib showed limited efficacy 
in patients with TNBC. Overall, two of 43 patients (5%) 
achieved a RECIST PR, both occurring in the lymph nodes 
and lasting for 14 and 58 weeks, respectively. In addition, 11 
of 43 patients (26%) experienced SD, including two lasting 
for 25 and 33 weeks. The mPFS was 8.3 weeks.
Another study demonstrated a significant reduction in 
cell viability and induction of apoptosis in TNBC cell lines 
using the three-drug combination of dasatinib, cetuximab, 
and cisplatin compared with the dual combination of cetux-
imab and cisplatin.152
wnt/Frizzled
Wnt signaling is a key oncogenic pathway in multiple cancers 
and regulates cell proliferation, migration, and differentia-
tion.153,154 Wnt proteins, which are secreted glycoproteins, bind 
to the low-density lipoprotein receptor-related protein 5/6 
(LRP5/6) and Frizzled (FZD), a seven-pass transmembrane 
receptor protein, to activate the Wnt/β-catenin signaling path-
way.155 In the absence of Wnts, β-catenin is sequestered in a 
complex, which results in the ubiquitination and the subsequent 
degradation of β-catenin by the 26S  proteasome. Conversely, 
when Wnt proteins are secreted from cells, they can form a 
ternary complex with the FZD and the LRP5/6 receptors, 
which results in the stabilization of cytosolic β-catenin. The 
β-catenin then translocates into the nucleus where it induces 
the expression of downstream target genes that regulate cell 
cycle, growth, and progression.156,157 Recently, two stud-
ies demonstrated that Wnt/β-catenin signaling activation is 
preferentially found in a subgroup of invasive TNBCs and is 
associated with a poor clinical outcome.158,159 This suggests 
that the Wnt/β-catenin signaling pathway plays an important 
role in TNBC development and progression.160
Multiple attempts to develop antibodies against key 
Wnt co-receptors, including LRP6 and FZD, have been 
reported,161–163 with varying degrees of success.
A O-acyltransferase Porcupine (PORCN) inhibitor, 
IWP2, has been reported to show good potency and speci-
ficity in inhibiting Wnt signaling in vitro.164,165 During the 
biosynthesis of Wnt ligands, Wnt undergoes posttranslational 
acylation (palmitoylation) that is mediated by PORCN, a 
membrane-bound oacyltransferase.166,167 PORCN is specific 
and dedicated to Wnt posttranslational acylation, which is 
required for subsequent Wnt secretion.168 Loss of PORCN 
leads to inhibition of Wnt ligand-driven signaling activities 
in knockout mouse models.168,169
A Phase I dose-escalation study of oral LGK974 is cur-
rently ongoing. The primary purpose of this study is to find 
the recommended dose of LGK974 that can be safely given 
to adult patients with malignancies (also patients with TNBC) 
dependent on Wnt ligands for whom no effective standard 
treatment is available.170
Discussion
TNBC is a heterogeneous disease at molecular, pathologic, 
and clinical levels. Stratification of TNBC into subclasses, 
using new markers, will identify new screening methods, 
prognostic factors, methodologies, and perhaps targets for 
personalized therapies. A lot of new targeted therapies are 
actually under study, but the efforts are not reaching the 
hoped results.
Anyhow, bevacizumab showed encouraging results in sev-
eral trials, as suggested by the meta-analysis of O’Shaughnessy 
et al.98 Unfortunately, mPFS advantage was not confirmed 
also by an advantage in mOS; this may be due to the several 
currently available post-progression therapies. However, 
bevacizumab is a well-known drug with a manageable toxicity 
profile, so it could be useful to further evaluate its action in this 
difficult patient setting. Meanwhile other anti-VEGF therapies, 
like TKIs, which have good results in other diseases, have 
shown all their limits in TNBC;  therefore, because TNBC is 
only a part of a larger BC  population, results have been limited 
to subgroup analysis in the majority of clinical trials.
Regarding the anti-EGFR therapies, there was a strong 
rationale for their use in TNBC treatment, particularly 
because of the correlation between EGFR hyper-expression 
and negative prognosis in this disease. Furthermore, in some 
trials cetuximab showed a positive trend to an OS advantage 
in this setting, even if those trials enrolled only a small 
number of patients. From these results, it seems that the 
subpopulation of TNBC appears to be more sensitive to these 
therapies; moreover, many efforts are under way to identify 
TNBC patients who benefit from cetuximab treatment, which 
may be correlated with lower expression of alpha-crystallin B 
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chain (encoded by the CRYAB gene), higher expression of 
PTEN homologue, and lack of KRAS expression in patients 
with BLBC.
In addition, erlotinib and gefitinib showed some actions 
in TNBC, but the experiences are too small to consider 
these results conclusive at all; furthermore, it seems that 
 BRCA-mutated TNBC achieves a better response with 
erlotinib. The mTOR inhibitor everolimus also needs further 
evaluation to clarify its real action in this clinical setting.
On the basis of preclinical studies, there was a lot 
expected from PARP inhibitors. Until now, olaparib has not 
been studied in a Phase III trial, while iniparib activity, which 
in a Phase II study seemed very promising, was not confirmed 
in the Phase III study. However, the BRCA-mutated popu-
lation seems to be the target of this drug family, so future 
clinical trials should be based on this class of TNBC.
Other target agents, even if based on fascinating theories, 
at the moment have not shown impressive achievement 
in the Phase I and Phase II trials in which they have been 
evaluated. Further investigations are needed, above all in 
translational studies involving the evaluation of predictive 
response biomarkers.
Anyhow, expression profiling and genomic studies are 
changing our view about the molecular biology of BC, which 
is currently considered as a group of distinct diseases from 
the molecular point of view. Indeed, although the important 
role of genomic studies – for example the assessment of p53 
status, HER2 amplification, BRCA1 and 2 deletions, and 
epigenetic and chromosomal modifications – most of the 
studies regarding the molecular signature of BC are actually 
related to the expression profile of tumors (ie, the messenger 
RNA or protein level). The morphologic features of tumor 
cells have long been validated for the clinical classification 
of BC and are regularly used as a “gold standard” to ascertain 
prognostic outcome in patients. Identification of molecular 
markers, such as expression of the receptors for estrogen 
and progesterone and HER2, has played an important role 
in determining targets for the development of efficacious 
drugs for treatment, and has also offered additional predic-
tive value for the therapeutic assessment of patients with BC. 
Currently, no routine specific diagnostic procedure exists for 
this subtype, and the patients’ management is similar to that 
of other subtypes regarding prevention, prognostic assess-
ment, and treatment.
However, the detailed molecular characterization of 
TNBC is ongoing, both to better understand the different biol-
ogy and clinical outcome, and to identify specific  diagnostic, 
prognostic, and therapeutic targets. In particular, one 
important goal is, therefore, the identification of  prognostic 
factors and markers to reliably select high- and low-risk sub-
sets of patients with TN disease, in order to explore different 
biologically based treatments and to tailor the therapeutic 
approaches to the single patient.
The more we learn about TNBC, the more we can improve 
therapies; in recent years, medical research has been fully 
oriented toward the targeted therapies; we hope to reach also 
with TNBC what happened with HER2 in BC and with more 
uncommon tumors, like kidney cancer and gastrointestinal 
stromal tumor. To achieve the best for targeted therapy, it 
seems necessary to study in detail the molecular subtype 
present in TNBC in a such way as to avoid that a therapy 
against a particular molecular feature is studied in a popula-
tion in which that trait is absent.
However, TNBC is clearly a complex disease; indeed 
the genetic heterogeneity is present not only in differently 
affected individuals, but also among tumors occurring at 
different sites within the same patient. As such, it is likely 
that its biology involves multiple redundancies and pathway 
cross-talk. If only one pathway is selectively inhibited, the 
efficacy of the therapeutic strategy would likely be under-
mined by activation of a compensatory pathway. Therefore, 
it is not surprising that, to date, not a single targeted therapy 
has been approved for the treatment of TNBC, for which 
cytotoxic chemotherapy remains the standard treatment. 
Combining two or more targeted agents may be required for 
a more rational and optimal approach to TNBC treatment. 
Alternatively, one technique that may show promise is gene 
therapy; in particular, gene transfer should correct abnormal 
genetic functions in cancer cells. Furthermore, these potential 
improvements are burdened with technical difficulties, such 
as insufficient infectivity or inadequately broad biodistribu-
tion of the transfer vector.
Conclusion
Important results have been achieved with antiangiogenic 
drugs, although much still needs to be improved.  Perspectives 
on new therapeutic molecules are most interesting, in particu-
lar the PARP inhibitors. The overall impact of these agents on 
patient survival has not been as great as expected, probably 
because the molecular basis of this illness needs to be bet-
ter understood so that treatment can be more appropriately 
tailored.
At the current time, we believe that the systematic 
evaluation of the predictive value of the genomic altera-
tions is critically important for further progress in this 
field; for this reason, there is the need for tissue collection 
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in the post-neoadjuvant and metastatic settings for a better 
 understanding of the relevant pathways that are associated 
with TNBC pathogenesis and therapeutic resistance.
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